Aptevo Therapeutics and the ADAPTIR™ (Modular Protein Technology) Platform: The Future of Immuno-oncology

Aptevo Therapeutics is a biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Our core technology is the ADAPTIR™ (modular protein technology) platform. We also have four commercial products that generate revenue in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immuno-oncology.


Recent Updates

Stock Details Stock Summary | APVO | Nasdaq $2.89 + 0.04 (1.40%)
Volume: 98,335
Updated November 21, 2017  4:00 p.m. ET
IR Contacts Primary IR Contact
Stacey L. Jurchison
Senior Director, Investor Relations & Corporate Communications
Phone: 206.859.6628
E-mail: jurchisons@apvo.com

29th Annual Piper Jaffray Healthcare Conference
AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics